Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ≥50% (vol 14, pg 1, 2022)

被引：0
|
作者：
Freemantle, N.
Xu, Y.
Wilson, F. R.
机构：
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2022年 / 14卷
关键词：
D O I：
10.1177/17588359221127078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis
    Peng, Tzu-Rong
    Lin, Hung-Hong
    Tsai, Fang-Pei
    Wu, Ta-Wei
    THORACIC CANCER, 2021, 12 (21) : 2873 - 2885
  • [22] PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis
    Rossi, Antonio
    Di Noia, Vincenzo
    Gkountakos, Anastasios
    D'Argento, Ettore
    Sartori, Giulia
    Vita, Emanuele
    Monteverdi, Sara
    Lombardo, Fiorella
    Iacovelli, Roberto
    Carbognin, Luisa
    Sperduti, Isabella
    Milella, Michele
    Tortora, Giampaolo
    Bria, Emilio
    Pilotto, Sara
    IMMUNOTHERAPY, 2019, 11 (10) : 921 - 930
  • [23] Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small-cell lung cancer: a network meta-analysis
    Chen, Jiarui
    Liu, Xingyu
    Zhang, Junhong
    Huang, Zhao
    Zeng, Wei
    Hu, Jing
    Chen, Gang
    Gong, Yan
    Liu, Yu
    Xie, Conghua
    FUTURE ONCOLOGY, 2022, 18 (13) : 1651 - 1664
  • [24] Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Gettinger, Scott
    Rizvi, Naiyer A.
    Chow, Laura Q.
    Borghaei, Hossein
    Brahmer, Julie
    Ready, Neal
    Gerber, David E.
    Shepherd, Frances A.
    Antonia, Scott
    Goldman, JonathanW.
    Juergens, Rosalyn A.
    Laurie, Scott A.
    Nathan, Faith E.
    Shen, Yun
    Harbison, Christopher T.
    Hellmann, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2980 - +
  • [25] PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis
    Garcia-Gonzalez, Jorge
    Ruiz-Banobre, Juan
    Afonso-Afonso, Francisco J.
    Amenedo-Gancedo, Margarita
    Areses-Manrique, Maria del Carmen
    Campos-Balea, Begona
    Casal-Rubio, Joaquin
    Fernandez-Nunez, Natalia
    Firvida Perez, Jose Luis
    Lazaro-Quintela, Martin
    Perez Parente, Diego
    Crama, Leonardo
    Ruiz-Gracia, Pedro
    Santome-Couto, Lucia
    Leon-Mateos, Luis
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 13
  • [26] Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China
    Teng, Meng-Meng
    Chen, Si-Ying
    Yang, Bo
    Wang, Yan
    Han, Rui-Ying
    An, Meng-Na
    Dong, Ya-lin
    You, Hai-Sheng
    CANCER MEDICINE, 2021, 10 (18): : 6344 - 6353
  • [27] Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: A systematic review and network meta-analysis
    Wang, Liming
    Yang, Yifan
    Yu, Jiangyong
    Zhang, Shuai
    Li, Xu
    Wu, Xiaonan
    Nie, Xin
    Liu, Wenbo
    Zhang, Ping
    Li, Yi
    Li, Ailing
    Ai, Bin
    THORACIC CANCER, 2022, 13 (03) : 322 - 337
  • [28] Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1
    Masuda, Takeshi
    Fujitaka, Kazunori
    Suzuki, Tomoko
    Hamai, Kosuke
    Matsumoto, Naoko
    Matsumura, Mirai
    Isoyama, Shoko
    Ueno, Sayaka
    Mito, Mineyo
    Yamaguchi, Kakuhiro
    Sakamoto, Shinjiro
    Kawano, Reo
    Masuda, Ken
    Nishino, Ryohei
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Hattori, Noboru
    THORACIC CANCER, 2022, 13 (11) : 1611 - 1618
  • [29] Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis
    Zhao, Mingye
    Shao, Taihang
    Ren, Yinan
    Zhou, Caicun
    Tang, Wenxi
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [30] Comparative efficacy and safety of first-line PD-1/PD-L1 inhibitors in immunotherapy for non-small cell lung cancer: A network meta-analysis
    Liu, Liyan
    Yan, Yilong
    Wang, Yuqiao
    Li, Ziming
    Yang, Li
    Yu, Kefu
    Zhao, Zhigang
    ONCOLOGY LETTERS, 2025, 29 (03)
12345